Event Information

Event Topic:
KLS-13019 – A Remarkable Non-Opioid Drug Discovery for the Treatment of Neuro Pain

Event Description:
KLS-13019 is a ground-breaking game changer in the field of small molecule medicine. The proven science behind KLS-13019 reveals a first-in-class drug for targeting GPR55, an important G-protein coupled receptor responsible for the early signaling and onset of inflammation. KLS-13019 is a non-opioid that has proven to reverse chemo induced neuropathic pain in animals. It is also a non-NSAID based compound which gives it strategic advantages to treat inflammation in patients who are on hypertension medication and cannot take NSAIDs. Additional animal studies have also shown that KLS-13019 can reduce morphine reward seeking in animals (addiction), as well as outperform morphine in treating osteoarthritis (inflammation).

Date/Time:
Date(s) - 04/02/24
8:15 am - 10:15 am

Event Location:
Zoom talk: https://us02web.zoom.us/j/88549236999:

Speaker Information

Event Speaker:
Dean Petkanas

Event Speaker Title:
Co-Founder & CEO

Event Speaker Company:
Kannalife Sciences

Event Speaker Bio:

Dean Petkanas is an executive management professional with over 25 years of banking, life sciences and capital markets experience. Mr. Petkanas co-founded Kannalife Sciences, Inc. (2010) and Neuropathix, Inc. (2018). He has been responsible for the creation and execution of the Company’s business model, the licensing of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” from the NIH, and co-inventor of two US Patents, #9611213 and #10004722, titled “Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” Mr. Petkanas led the team effort in obtaining $3.3 million in grants from the NIH to fund IND enabling studies for KLS-13019.

Event Details

Cost:
$0

Add To Calendar